1. Introduction {#sec1}
===============

The new European guidelines for heart failure define three groups based on ejection fraction (EF): a group with reduced EF \< 40% (left ventricular systolic dysfunction (LVSD)); a group in the grey zone with EF in the midrange 40--49%; and a group with preserved EF ≥ 50%. It is concluded that patients in the grey zone probably have mild systolic dysfunction and the reason for creating a separate group is to stimulate research into characteristics, pathology, and treatment of this group of patients \[[@B1]\]. A problem related to the grey zone is an uncertain definition of LVSD, as shown and described in the echocardiographic study of the present study \[[@B2]\].

Left ventricular systolic dysfunction affects about 2% of the population in the western world, including many with unrecognized LVSD. It accumulates in the elderly population because LVSD is the final stage in most cardiac diseases, mostly caused by atherosclerosis in the coronary arteries \[[@B3]\]. The prognosis is grave, but treatment can delay progression and reduce morbidity and mortality. Screening for systolic heart failure in high risk populations should be considered because correct diagnosis is the cornerstone of effective treatment.

Echocardiography is the gold standard to diagnose LVSD, but access is limited, and referral to echocardiography requires a well-founded suspicion of LVSD \[[@B3]\]. Thus it is pivotal to look for new biomarkers, which might also give a better insight into the pathophysiology because LVSD is a complex disorder with hemodynamic, metabolic, neurohormonal, inflammatory, and immunological changes \[[@B4]\]. New biomarkers should be validated against established biomarkers.

B-type natriuretic peptide (or brain natriuretic peptide (BNP)) and N-terminal fragment-proBNP (NT-proBNP) are well established as diagnostic and prognostic biomarkers in LVSD, and combination with ECG might increase the specificity and the ability to screen for LVSD in high-risk populations \[[@B5], [@B6]\]. NT-proBNP synthesis is initiated by LVSD via neurohormonal activation and increased wall stress in the heart, and it is a hemodynamic cardiac marker. Uric acid is an old biomarker that may be ready for a renaissance \[[@B7]\].

Almost every disease and any injury to the body are accompanied by inflammation and activation of the immune system. The inflammatory system is complex and crucial for survival, but it is a double-edged sword. In LVSD, proliferation of monocytes and macrophages is observed. There is an increase in harmful oxygen-free radicals, primarily produced by xanthine oxidase; uric acid reflects xanthine oxidase activity. Proinflammatory cytokines with detrimental effects on myocardial function include tumour necrosis factor- (TNF-) *α*, interleukin-1, and interleukin-6 \[[@B4], [@B8]--[@B10]\]. These evoke a counterbalance reaction with increased production of anti-inflammatory interleukin-10 and HLA-G \[[@B11], [@B12]\].

This study aims to evaluate HLA-G as a new biomarker for LVSD. Human leukocyte antigen (HLA)-G is an HLA class Ib molecule with immunomodulatory, immunosuppressive, and tolerance-inducing functions \[[@B13]\]. It is well described in pregnancy protecting the fetus from an immune response from the mother. It is associated with a lower risk of rejection of a transplanted organ, \[[@B13]--[@B16]\], and, in cases of heart transplantations, myocardial expression of HLA-G has been significantly correlated with low risk of rejection \[[@B17]\]. In contrast, in pathological conditions, like infections and cancer, in which a vigorous and maintained immune response is desirable, the expression of HLA-G is detrimental. In cancer, it has deleterious escape-effects and the expression of HLA-G by the tumour cells seems to accelerate relapse \[[@B18]\]. The HLA-G protein has under normal conditions a very restricted expression pattern \[[@B13]\]. It is expressed during pregnancy by extravillous cytotrophoblast cells at the fetomaternal interface and is important for inducing maternal tolerance to the semiallogenic fetus \[[@B19], [@B20]\]. Furthermore, HLA-G is expressed by certain monocytes, T cells, and dendritic cells \[[@B21]\]. Four membrane-bound HLA-G isoforms and three soluble HLA-G isoforms generated by alternative splicing have been reported \[[@B13], [@B22]\]. Membrane-bound full-length HLA-G1 can also be cleaved from the cell surface by metalloproteinases \[[@B23]\].

A single published study has indicated that soluble HLA-G (sHLA-G) in plasma is upregulated in patients with systolic heart failure, compared to healthy controls, and independent of NYHA class, EF, and other biomarkers \[[@B24]\]. The study included only ten control subjects who were markedly younger than the participants in the present study. The current study compares sHLA-G with the state-of-the-art biomarker NT-proBNP and with uric acid, both independent biomarkers, in order to clarify if sHLA-G in blood plasma can be used as a biomarker for LVSD in a group of high-risk elderly persons. For the first time, two polymorphisms in the HLA-G gene are investigated in relation to EF. Several studies have indicated that these polymorphisms modulate HLA-G expression.

2. Materials and Methods {#sec2}
========================

2.1. Patients and Samples {#sec2.1}
-------------------------

Individuals ≥ 75 years old from the general population and from a heart failure clinic, with heart disease risk factors or with former or present cardiac disease, especially LVSD, as well as healthy persons, were invited to participate. Two hundred and sixty subjects were included in the study. All participants provided written informed consent and the study was carried out in accordance with the ethical standards of the Declaration of Helsinki and was approved by the local ethics committee of Region Zealand and the Danish Data Protection Agency. Baseline characteristics of the study subjects are shown in [Table 1](#tab1){ref-type="table"}.

While resting in supine position at room temperature all of the 260 subjects had a blood sample taken. Blood samples were obtained as EDTA plasma and heparin plasma samples, whole blood (EDTA tubes), and serum, with rapid flow from a large antecubital vein using standard venipuncture techniques. For the plasma samples, subsequently, centrifugation was performed to obtain platelet-poor plasma. The plasma supernatant was separated and the aliquot was transferred to cryotubes. All blood aliquots were stored at −80°C until analyzed.

Within the same hour a transthoracic echocardiography was performed by an experienced level 3 echocardiographer using General Electric Vingmed Vivid 7 or 9 and MJS probe 1.5--4.0 MHz and following guidelines from the Danish Society of Cardiology. Based on EF the study subjects were divided into four groups: (1) ≥50% (preserved EF, considered as normal), (2) midrange EF 40--50%, (3) LVSD with EF of 30--40%, and (4) LVSD with EF \< 30%. Presence of moderate or severe valvular dysfunction was registered.

2.2. ELISA for Full-Length sHLA-G (The sHLA-G1 and HLA-G5 Isoforms) {#sec2.2}
-------------------------------------------------------------------

The level of sHLA-G1/HLA-G5 molecules in blood plasma samples was determined by a commercially available sandwich enzyme immunoassay (ELISA) (EXBIO, Praha, Czech Republic) according to the manufacturer\'s instructions. This ELISA specifically detects sHLA-G1 and HLA-G5 in a *β*2-microglobulin- (*β*2m-) associated form. Samples were analyzed in duplicate on two independent assay plates, always with the same calibrators and positive and negative controls on each plate, and the first set of samples was also reanalyzed as the last samples to secure the reproducibility and precision of the assay. Blood plasma samples were diluted 1 + 3 with the provided Dilution Buffer (60 *μ*L samples to 180 *μ*L Dilution Buffer). Samples were thawed and mixed thoroughly and 100 *μ*L of diluted plasma were loaded in duplicate onto microtiter plates precoated with the monoclonal antibody MEM-G/9 (anti-HLA-G1/G5). The plates were then incubated overnight at 4°C (with no shaking). Following five washing steps with 350 *μ*L of the supplied washing buffer, 100 *μ*L of conjugate solution was added and the plates were incubated at room temperature (RT) for one hour. The conjugate solution consisted of monoclonal anti-human *β*2-microglobulin antibody labeled with horseradish peroxidase (HRP). After five additional washing steps, 100 *μ*L of substrate solution with tetramethylbenzidine (TMB) were added to the plate, and the plate incubated once more at RT for 25 min with no shaking. Finally, 100 *μ*L of acidic stop solution were added to the plates. The plates were then analyzed using a microplate reader. The assay was performed in a BEP2000 ELISA robot instrument (Siemens Healthcare Diagnostics, Germany).

2.3. Analysis of NT-proBNP and Uric Acid {#sec2.3}
----------------------------------------

NT-proBNP was measured on the Elecsys 2010 system (Roche Diagnostics). The assay is an electrochemiluminescent sandwich immunoassay that uses two polyclonal antibodies directed at residues 1--21 and 39--50 of the NT-proBNP molecule. The CV% of the assay is 3.2--2.4% from 20.7 to 585.5 pmol/L (175--4,962 ng/L) with an analytical range of 0.6--4138.6 pmol/L (5--35,000 ng/L). Plasma uric acid was measured on ARCHITECT ci8200 Integrated System (Abbott Diagnostics, North Chicago, IL, USA). One NT-proBNP test failed reducing the total number of study participants with a NT-proBNP test result to 259.

2.4. Genotyping of the 14 bp Insertion/Deletion Polymorphism (rs66554220) and the +3142 Single-Nucleotide Polymorphism (rs1063320) in the 3′-Untranslated Region of the HLA-G Gene {#sec2.4}
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

EDTA blood samples were carefully thawed and mixed thoroughly before processing. The DNA purification, using a Maxwell® 16 DNA Purification Kit, was performed in accordance with the manufacturer\'s instructions, and genomic DNA was stored at −20°C for further use. The real-time TaqMan PCR assay for genotyping of the HLA-G 14 bp insertion/deletion (ins/del) polymorphism in exon 8 (rs66554220) was performed using a LightCycler480 instrument (Roche Diagnostics, Switzerland) and performed as described by Djurisic et al. \[[@B25]\]. The genotyping of the +3142 SNP in the 3′UTR of the HLA-G gene (rs1063320) was performed as described by Bortolotti et al. \[[@B26]\].

2.5. Statistical Analysis {#sec2.5}
-------------------------

Specific*a priori* hypotheses were formulated. Each variable was tested for Gaussian (normal) distribution. In cases of a normal distribution, parametric tests were used (one-way ANOVA and unpaired *t*-test). Else, nonparametric tests were used (Kruskal-Wallis test, Mann--Whitney *U* test, and Jonckheere-Terpstra test). Receiver Operating Characteristic (ROC) curves were drawn for sHLA-G, proBNP, and uric acid. Charlson comorbidity index was calculated as described by Hall et al. \[[@B27]\]. Statistical analyses were made with the use of IBM SPSS version 22.0. Graphs were made in GraphPad Prism version 6 and IBM SPSS.

3. Results {#sec3}
==========

3.1. Characteristics of the Study Group {#sec3.1}
---------------------------------------

[Table 1](#tab1){ref-type="table"} shows the baseline characteristics of the study group (EF \< 40%) versus the control group (EF ≥ 40%). According to echocardiography there were 154 (59.2%) subjects with EF ≥ 50%, 106 (40.8%) subjects with EF \< 50%, 45 with EF 40--50%, and 61 (23.5%) with EF \< 40% (30 with EF 30--40% and 31 with EF \< 30%); 55 subjects had mitral or aortic valvular dysfunction to some degree, no one had severe valvular disease, and 20 patients with valvular disease also had LVSD.

3.2. Soluble HLA-G Levels in Blood Plasma Are Associated with Heart Failure {#sec3.2}
---------------------------------------------------------------------------

Soluble HLA-G in the blood plasma was significantly and uniformly higher in the two LVSD groups with EF \< 30% and EF 30--40% and in the midrange group with EF 40--50%, compared to the group with preserved EF ≥ 50% (*p* \< 0.0001, Kruskal-Wallis test ([Figure 1](#fig1){ref-type="fig"} and [Table 2](#tab2){ref-type="table"})). The values of NT-proBNP and uric acid were increased with decreasing EF ([Table 2](#tab2){ref-type="table"}). Furthermore, Receiver Operating Characteristic (ROC) curves showed that NT-proBNP outperformed both sHLA-G and uric acid as a biomarker of LVSD (Figures [2](#fig2){ref-type="fig"} [](#fig3){ref-type="fig"}--[4](#fig4){ref-type="fig"}).

There was no correlation between sHLA-G and uric acid, neither in the whole population nor in the patients with LVSD (Spearman, *p* = 0.295, *n* = 256; *p* = 0.529, *n* = 105).

There was a significant higher level of sHLA-G in cases of significant valvular heart disease for the whole study population of 260 subjects (*p* = 0.002, Mann--Whitney test [Figure 5(a)](#fig5){ref-type="fig"}). However, there was only a trend for the fraction of the population without LVSD (*p* = 0.067; [Figure 5(b)](#fig5){ref-type="fig"}).

3.3. HLA-G Gene Polymorphisms and Association with Risk of Heart Failure {#sec3.3}
------------------------------------------------------------------------

There were no significant differences in the distributions of the 14 bp ins/del genotypes between the different EF groups ([Table 3](#tab3){ref-type="table"}; *p* = 0.82, Chi-Square test). However, there was a tendency, when the group with EF \> 40% was compared with the group with EF \< 40% (*p* = 0.10, Chi-Square test). In the group with EF \> 40%, the frequency of the Ins 14 bp/Ins 14 bp genotype was 19.1% and only 8.2% in the group with EF \< 40% ([Table 3](#tab3){ref-type="table"}).

This difference was statistically significant, when the combined haplotype of the two HLA-G gene polymorphisms, the 14 bp ins/del and the +3142 SNP, was analyzed ([Table 4](#tab4){ref-type="table"}; *p* = 0.033, Chi-Square test). The combined genotype of the haplotype InsG/InsG was more frequent among subjects with EF \> 40% than among patients with EF \< 40%; the opposite was observed for the DelG/InsG combination of haplotypes.

In a separate analysis of the +3142 HLA-G SNP alone, no differences were observed in the distributions of the three genotypes between the group with EF \< 40% and the group with EF \> 40%. For the group with EF \> 40%, the frequencies were C/C (32.2%), C/G (43.7%), and G/G (24.1%). For the group with EF \< 40%, they were C/C (32.8%), C/G (44.3%), and G/G (23.0%).

4. Discussion {#sec4}
=============

This study shows that sHLA-G is increased in patients with EF \< 40 compared to patients with EF ≥ 40%. There was no difference in the concentration of sHLA-G in LVSD patients with EF \< 30% and with EF between 30 and 40%. Thus, sHLA-G in the blood plasma does not indicate the severity of LVSD, and, in accordance with the study by Almasood et al., we conclude that sHLA-G is a very sensitive LVSD biomarker \[[@B8], [@B9], [@B24]\]. The assay used in the current study detects both soluble HLA-G5 and soluble HLA-G1 associated with *β*2-microglobulin. The source of sHLA-G in the blood from men and nonpregnant women is not well established but is probably derived from immune cells \[[@B21]\]. It can be speculated that the raise in sHLA-G associated with LVSD might originate from activated immune cells or from the heart.

Neither sHLA-G nor serum uric acid is comparable with NT-proBNP as LVSD-biomarker, primarily due to a poor specificity \[[@B5]\]. Soluble HLA-G is influenced by many other conditions, for example, cancer and autoimmune disease, which may confound the analysis and the results and reduce the suitability of sHLA-G as a biomarker for LVSD.

Specificity may be increased by genotyping for the combined haplotypes of the two tested HLA-G gene polymorphisms. An interesting novel finding in the current study was that the distribution of the combined haplotypes of the two tested HLA-G gene polymorphisms, the 14 bp ins/del and the +3142 SNP in the 3′UTR of the gene, was statistically significant between the subjects with EF \> 40% and patients with EF \< 40% ([Table 4](#tab4){ref-type="table"}; *p* = 0.033). InsG/InsG was more frequent among subjects with EF \> 40% than patients with EF \< 40%; the opposite was observed for DelG/InsG. Interestingly, in healthy blood donors, the Ins 14 bp/Ins 14 bp HLA-G genotype has been significantly associated with low sHLA-G levels in the blood in several studies \[[@B28], [@B29]\]. Furthermore, the DelG/InsG combination has also been associated with a higher level of sHLA-G than the InsG/InsG combination, for example, in patients with multiple sclerosis; however, the DelC/DelC combination showed the highest concentrations of sHLA-G in the same study \[[@B30]\]. This is supported by the observations in the current study, which could indicate that specific HLA-G gene polymorphisms or haplotypes might influence the sHLA-G level in the blood and thereby the individual sHLA-G response in specific patients with systolic heart failure. It is not known whether this is due to genetic or epigenetic factors or if it is an adaptive mechanism triggered by the inflammatory process \[[@B19], [@B20]\].

There are certain limitations to the present study. One limitation of the current study is that the number of study participants is rather small; however, it is still the largest study until now regarding HLA-G in subjects with and without systolic heart failure. The study reflects clinical practice. The diagnosis of heart failure is uncertain for the small group with EF in the grey zone of 40--50%, but echocardiography is the standard diagnostic test and in this study performed by the most qualified \[[@B1], [@B2]\]. Important confounding factors are morbidities other than systolic heart failure, and these are common and inevitable ([Table 1](#tab1){ref-type="table"}).

One of the reactions of the body to injury is inflammation represented in this study by serum uric acid, which might trigger an immunologic response represented in this study by sHLA-G \[[@B10]\]. Both are biomarkers of LVSD, and thus inflammation and immune modulation seem to be involved in LVSD. This is in accordance with accumulating evidence that systemic and persistent inflammatory disorders predispose to cardiovascular diseases. This is the case in gout, rheumatoid arthritis, psoriasis, inflammatory bowel disease, lupus erythematosus, sclerosis disseminatus, and other autoimmune diseases and in chronic infections and cancers \[[@B4], [@B5], [@B18], [@B31]\]. It is also observed in conditions associated with long-lasting low grade inflammation and endothelial dysfunctions like atherosclerosis, diabetes mellitus, the metabolic syndrome, venous thromboembolism, smoking, and affective disorders and in chronic heart failure \[[@B4], [@B12]\]. Upregulation of HLA-G is present in most of these disorders, which nevertheless are dominated by inflammation \[[@B18]\]. Out-of-balance inflammation with persistent rise in inflammatory cytokines seems to be the common denominator for many potentially coherent diseases and disorders, and it acts self-reinforcing in a complex vicious circle \[[@B4]\]. The inflammatory triggers and mediators are poorly understood, but they promote and regulate the inflammatory cascade that predisposes to, for example, atherosclerosis and LVSD \[[@B31]\].

HLA-G is elevated in many conditions, and thus there is a lack of diagnostic precision and specificity, which may obscure evaluation of the significance of HLA-G as a biomarker of LVSD in a multimorbid ageing population like the one in the current study. Furthermore, it cannot be determined from the current study, which role sHLA-G might have in the pathogenesis and the clinical course and prognosis of LVSD and whether it is a simple marker or participate in LVSD.

Likewise, the pathophysiologic effect of uric acid in LVSD is unknown. Serum uric acid has a negative correlation with EF \[[@B8], [@B9]\]. It is an independent risk factor for LVSD, but it is not known if it is cause, consequence, or simply an epiphenomenon. The serum uric acid concentration is increased in patients with chronic LVSD, probably due to both reduced renal excretion and augmented production \[[@B8], [@B9]\]. Low-sodium diet, diuretics, and insulin resistance may increase reabsorption of uric acid. Cardiac and renal disorders are related and as cardiac function deteriorates with falling cardiac output, the glomerular filtration rate (GFR) falls, which leads to a reduction in renal uric acid excretion \[[@B10]\]. At the same time the inflammatory process associated with the chronic diseases accelerates, which contributes to an increase in serum uric acid, TNF, interleukin-1 and interleukin-6, and other cytokines and in sHLA-G \[[@B7]\]. The simultaneous elevation of uric acid and sHLA-G might represent different aspects of the same process, acting in negative feedback as proinflammatory and anti-inflammatory markers.

In LVSD there is an imbalance between proinflammatory and anti-inflammatory cytokines \[[@B32]\]. The clinical significance remains to be determined. There are indications that the prognosis may be improved by restraining the inflammatory process, and an increase in EF in LVSD has been observed following treatment with, for example, thalidomide, pentoxifylline, intravenous immunoglobulin, glucocorticoid, colchicines, methotrexate, biological agents, interleukin-10, influenza vaccination, HIV-therapy, antidiabetic sodium glucose cotransporters, and antidepressant drugs \[[@B4], [@B12], [@B32], [@B33]\]. However, no improvement was observed in a variety of antibiotic trials and in studies antagonizing TNF in patients with LVSD, and there have been mixed results in studies of the use of allopurinol, which inhibits xanthine oxidase \[[@B4], [@B8], [@B11], [@B12], [@B31]\]. In the future, therapies directed at downregulating or inhibiting inflammation may reduce atherosclerosis and its complications including heart failure \[[@B33]\]. Further studies are needed to elucidate the role of HLA-G in this scenario.

5. Conclusion {#sec5}
=============

For the first time, it was shown in the current study that a combined haplotype (DelG/InsG) of two HLA-G gene polymorphisms, the 14 bp ins/del and the +3142 SNP, were more frequent among patients with EF \< 40% than among subjects with EF ≥ 40%. The opposite was observed for the combined haplotype InsG/InsG. This probably influences the sHLA-G level in the blood, and this study also showed that sHLA-G was increased in patients with EF \< 40 compared to patients with EF ≥ 40%.
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![Soluble HLA-G in peripheral blood in relation to left ventricular ejection fraction (box and whiskers plot, min. to max., all points shown; *p* \< 0.001, Kruskal-Wallis test; Dunn\'s multiple comparisons test, ^*∗*^ *p* \< 0.05, ^*∗∗*^ *p* \< 0.01) (one NT-proBNP test failed in the group with ejection fraction \>50% reducing the number to 153).](JIR2016-8417190.001){#fig1}

![(a) Receiver Operating Characteristic (ROC) curve of soluble HLA-G with heart failure defined as ejection fraction \<50%. Area under the curve is 0.676, *p* \< 0.001. (b) Receiver Operating Characteristic (ROC) curve of soluble HLA-G with heart failure defined as ejection fraction \<40%. Area under the curve is 0.639, *p* = 0.001.](JIR2016-8417190.002){#fig2}

![(a) Receiver Operating Characteristic (ROC) curve of NT-proBNP with heart failure defined as ejection fraction \<50%. Area under the curve is 0.811, *p* \< 0.001. (b) Receiver Operating Characteristic (ROC) curve of NT-proBNP with heart failure defined as ejection fraction \<40%. Area under the curve is 0.902, *p* \< 0.001.](JIR2016-8417190.003){#fig3}

![(a) Receiver Operating Characteristic (ROC) curve of uric acid with heart failure defined as ejection fraction \<50%. Area under the curve is 0.721, *p* \< 0.001. (b) Receiver Operating Characteristic (ROC) curve of uric acid with heart failure defined as ejection fraction \<40%. Area under the curve is 0.788, *p* \< 0.001.](JIR2016-8417190.004){#fig4}

![(a) Soluble HLA-G in peripheral blood in relation to significant valvular heart disease (box and whiskers plot, min. to max., all points shown; *p* = 0.002, Mann--Whitney test). (b) Soluble HLA-G in peripheral blood in relation to significant valvular heart disease in patients without heart failure (EF \> 50%) (box and whiskers plot, min. to max., all points shown; *p* = 0.067, Mann--Whitney test).](JIR2016-8417190.005){#fig5}

###### 

Baseline characteristics of the study population (LVSD, EF ≤ 40%) compared to the control group (EF \> 40%).

  Characteristics                             Ejection fraction ≤ 40%         Ejection fraction \> 40%   All together                                                      
  ------------------------------------------- ------------------------------- -------------------------- ----------------------------- ---- ------------------------------ ----
  Age (years)                                 81                                                         80                                 80 (75--92)                     
  Gender                                                                                                                                                                    
   Females                                    14                              23                         119                           60   134                            52
   Males                                      47                              77                         80                            40   126                            48
  Body mass index (BMI) (kg/m^2^)             26.1                                                       25.4                               25.6                            
  Smoking                                                                                                                                                                   
   Present                                    8                               13                         18                            9    26                             10
   Ex-smoker                                  35                              57                         95                            48   130                            50
   Never smoker                               18                              30                         86                            43   104                            40
  History                                                                                                                                                                   
   Angina pectoris                            25                              41                         52                            26   77                             30
   Acute Myocardial Infarction (AMI)          31                              51                         24                            12   55                             21
   Percutaneous Coronary Intervention (PCI)   12                              20                         27                            14   39                             15
   Coronary Artery Bypass Grafting (CABG)     15                              25                         15                            8    30                             12
   Dilated cardiomyopathy                     10                              16                         5                             3    15                             6
   Valvular disorder                          17                              29                         12                            6    29                             11
   Valvular substitution                      6                               10                         4                             2    10                             4
   Arrhythmias                                45                              74                         47                            24   92                             35
   Atrial fibrillation P-P-P                  38                              62                         37                            19   75                             29
   Pacemaker                                  25                              41                         4                             2    29                             11
   Hypertension                               41                              67                         132                           66   173                            67
   Diabetes mellitus                          15                              25                         22                            11   37                             14
   Hypercholesterolaemia                      41                              67                         103                           52   144                            55
   Thyroidal disease                          6                               10                         25                            13   31                             12
   Cerebrovascular disease                    14                              23                         29                            15   43                             17
   Peripheral arterial disease                10                              16                         13                            7    23                             9
   Lung disease                               27                              44                         40                            20   67                             26
   Gastrointestinal disorder                  33                              54                         91                            46   124                            48
   Renal disorder (moderate-severe)           10                              16                         11                            6    21                             8
   Musculoskeletal disease                    41                              67                         119                           60   160                            62
   Autoimmune disease                         4                               7                          16                            8    20                             8
   Anemia                                     10                              16                         11                            6    21                             8
   Cancer                                     14                              23                         54                            27   68                             26
  Charlson comorbidity index                  3.7                                                        1.5                                2.0                             
   Corrected for age                          7.3                                                        4.9                                5.5                             
  QRS-duration                                138                                                        94                                 104                            
  Medical treatment                                                                                                                                                         
   Thrombocyte inhibitor                      36                              59                         82                            41   118                            45
   AK                                         23                              38                         30                            15   53                             20
   Statin                                     35                              57                         74                            37   109                            42
   Diuretics                                  46                              75                         74                            37   120                            46
   Diuretics (Centyl)                         10                                                         49                                                                 
   Diuretics (Furosemide)                     32                                                         23                                                                 
   Aldosterone-antagonist                     18                              30                         8                             4    26                             10
   ACE-inhibitor                              34                              56                         42                            21   76                             29
   ATII                                       14                              23                         32                            16   46                             18
   Beta-blockers                              49                              80                         61                            31   110                            42
  Clinical chemistry                          Mean                                                       Mean                               Mean                            
   Hemoglobin (mmol/L)                        8.1                                                        8.2                                8.2                             
   Potassium (mmol/L)                         4.0                                                        3.8                                3.9                             
   Sodium (mmol/L)                            139                                                        139                                139                             
   Creatinine (*µ*mol/L)                      116                                                        84                                 92                              
   GFR                                        55                                                         69                                 66                              
   C-reactive protein (CRP) (mg/L)            5.0                                                        4.5                                4.6                             
   Thyroid stimulating hormone (TSH) (mU/L)   1.3                                                        1.6                                1.5                             
   Albumin (g/L)                              39                                                         41                                 41                              
   Alanine aminotransferase (ALAT) (U/L)      20                                                         21                                 21                              
   Uric acid (mmol/L)                         0.49                                                       0.35                               0.38                            
   Glucose (mmol/L)                           6.6                                                        5.9                                6.1                             
   NT-proBNP (pmol/L)                         268                                                        50                                 101                             
   Soluble HLA-G (U/mL)                       71 (12--1144) (median, range)                              52 (4--960) (median, range)        61 (4--1144) (median, range)    

###### 

The distribution of soluble HLA-G (U/mL), NT-proBNP (pmol/L), and uric acid (mmol/L) according to the left ventricular ejection fraction (median, range).

  Parameter              All study population   *n*   Left ventricular ejection fraction                                           
  ---------------------- ---------------------- ----- ------------------------------------ ------------------- ------------------- -------------------
  Soluble HLA-G (U/mL)   61 (4--1144)           259   44 (4--960)                          90 (11--758)        71 (12--1144)       71 (14--331)
  NT-proBNP (pmol/L)     35 (4--1620)           259   24 (4--347)                          41 (7--273)         134 (21--389)       307 (69--1620)
  Uric acid (mmol/L)     0.37 (0.18--0.92)      257   0.34 (0.18--0.87)                    0.37 (0.20--0.68)   0.44 (0.19--0.80)   0.44 (0.19--0.92)

###### 

Distribution of genotypes of the 14 bp insertion/deletion polymorphism in the 3′-untranslated region of the HLA-G gene in relation to left ventricular ejection fraction.

  Ejection fraction   Del 14 bp/Del 14 bp   Del 14 bp/Ins 14 bp   Ins 14 bp/Ins 14 bp   Total
  ------------------- --------------------- --------------------- --------------------- --------------
  \>50%^a^            61 (39.6%)            66 (42.9%)            27 (17.5%)            154 (100.0%)
  40% to 50%          17 (37.8%)            17 (37.8%)            11 (24.4%)            45 (100.0%)
  30% to 40%          12 (40.0%)            16 (53.3%)            2 (6.7%)              30 (100.0%)
  \<30%               12 (38.7%)            16 (51.6%)            3 (9.7%)              31 (100.0%)
                                                                                        
  \>40%^b^            78 (39.2%)            83 (41.7%)            38 (19.1%)            199 (100.0%)
  \<40%^b^            24 (39.3%)            32 (52.5%)            5 (8.2%)              61 (100.0%)

  ^a^ *p* = 0.82 (Chi-Square test, 0.40, df = 2); ^b^ *p* = 0.10 (Chi-Square test, 4.57, df = 2).

###### 

Distribution of haplotypes of the 14 bp insertion/deletion polymorphism (Del/Ins) and the +3142 SNP (C/G) in the 3′-untranslated region of the HLA-G gene in relation to left ventricular ejection fraction.

  Ejection fraction   DelC/DelC    DelC/DelG   DelC/InsC   DelC/InsG    DelG/DelG   DelG/InsG   InsG/InsG    Total
  ------------------- ------------ ----------- ----------- ------------ ----------- ----------- ------------ --------------
  \>40%^a^            62 (31.2%)   15 (7.5%)   1 (0.5%)    74 (37.2%)   1 (0.5%)    8 (4.0%)    38 (19.1%)   199 (100.0%)
  \<40%^a^            20 (32.8%)   4 (6.6%)    0 (0.0%)    23 (37.7%)   0 (0.0%)    9 (14.8%)   5 (8.2%)     61 (100.0%)

  ^a^ *p* = 0.033 (Chi-Square test, 10.50, df = 4), for the Chi-Square test DelC/InsG was added to the DelC/DelC group and DelG/DelG was added to the DelG/InsG group.

[^1]: Academic Editor: Enrico Fainardi
